SCHEMBL3576469

SCHEMBL3576469

CCNc1ccc(Cl)nc1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.44
ALDH1A1 P00352 2/20 0.44
GAA P10253 2/20 0.44
HTT P42858 2/20 0.44
KDM4E B2RXH2 1/20 0.44
THRB P10828 1/20 0.44
HPGD P15428 1/20 0.44
GFER P55789 1/20 0.44
PLEC Q15149 1/20 0.44
FABP4 P15090 1/20 0.42
HCAR3 P49019 2/20 0.40
PIK3CA P42336 4/20 0.39
ATM Q13315 1/20 0.39
KMT2A Q03164 4/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 3/20 0.37
PGK1 P00558 1/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
MAPK1 P28482 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11713260 0.83 CCNA2 (0.45) MAPTALDH1A1GAAHTTKDM4E
SCHEMBL30473132 0.81 ALDH1A1 (0.40) MAPTALDH1A1GAAKDM4EFABP4
SCHEMBL3577408 0.81 ALDH1A1 (0.40) MAPTALDH1A1GAAKDM4EFABP4
SCHEMBL16517241 0.80 MAPT (0.44) MAPTALDH1A1GAAHTTKDM4E
SCHEMBL6756876 0.80 ATM (0.59) MAPTALDH1A1GAAKDM4EHPGD
SCHEMBL2342690 0.79 ALDH1A1 (0.40) MAPTALDH1A1GAAHTTKDM4E
SCHEMBL1890402 0.75 TDP1 (0.42) MAPTALDH1A1KDM4EPIK3CAATM
Clopyralid SCHEMBL5076706 0.74 KMT2A (0.48) MAPTALDH1A1GAAKDM4EATM
SCHEMBL720894 0.73 GABRP (0.42) MAPTALDH1A1GAAHTTKDM4E
SCHEMBL1642783 0.73 LMNA (0.38) MAPTALDH1A1GAAHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US claimed
EP-1984340-B1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-06-27 EP disclosed
CN-101379036-B Anthranilamide/2-amino-heteroarene carboxamide derivatives HOFFMANN LA ROCHE 2011-06-01 CN disclosed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
CN-101379036-A Anthranilamide/2-amino-heteroarene carboxamide derivatives HOFFMANN LA ROCHE (CH) 2009-03-04 CN disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC MAPT 2786/4885ALDH1A1 1414/4885GAA 450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.